Herewith, as a result of benznidazole treatment, a downregulation of CCL5 is observed in both IND and CCC I patients, supporting a decreased cytotoxic activity of CD8+ T cells in treated patients and a reduction of inflammation, which is directly related to a decrease in infection-induced cardiac tissue damage. This evidence concerns the gene CCL5 and infection.